 | Info
Sheets |
| | | | | | | | | | | | | | | | | | | | | | |
 | Out-
side |
| | | | |
|
| | | | |
Result : Searchterm 'Viscosity' found in 1 term [ ] and 4 definitions [ ]
| | 1 - 5 (of 5) Result Pages : [1] | |  | | |
 |
MRI Resources |
|
| | | | | |  |
| |
|
| A property of a fluid or semi-fluid that affects its mobility, and therefore its intensity in an image. |
| | | | | |
| |  |
| Diffusion |  |
| |
|
The process by which molecules or other particles intermingle and migrate due to their random thermal motion. Microscopic particles are jittering around with translational and rotational motions as a result of their thermal energy, which is half the Boltzmann constant multiplied by the absolute temperature of the system (˝kT) per degree of freedom (3 directions of translation and 3 directions of rotation for ordinary particles).
MRI provides a sensitive technique for measuring diffusion of some substances. These diffusive processes mean that particles reach areas of low from areas of high concentration, thus leading to equilibration.
In body fluids, the distribution of capillaries within tissues is such that transport over macroscopic distances is accomplished by the blood circulation, while over intercapillary distances substances are carried by diffusion. The fluid diffusion constant is itself inversely proportional to the viscosity and the radius of the diffusing particles.
See also Diffusion Tensor Imaging and Diffusion Weighted Imaging.
|
| | | |
 Further Reading: |
Basics:
|
|
News & More:
| | | | | | •• There are 12 news about 'Diffusion'. | |
| |
|
MRI Resources |
|
| | | | | |
|
| |
| MultiHance® |   |
| |
|
MultiHance® is a paramagnetic contrast agent for use in diagnostic magnetic resonance imaging (MRI) of the liver and central nervous system. MultiHance® is a small molecular weight chelate, which tightly binds the Gd atom. The substance is excreted partly by the kidneys, partly by the biliary system, which is especially unique.
MultiHance® is indicated, for the detection of focal liver lesions in patients with known or suspected primary liver cancer (e.g. hepatocellular carcinoma) or metastatic disease.
MultiHance® is also indicated in brain MRI and spine MRI where it improves the detection of lesions and provides diagnostic information additional to that obtained with unenhanced MRI.
Gd-BOPTA–enhanced MRA can provide superior vascular signal intensity and SNR, as compared with Gd-DTPA, due to its higher relaxivity, even at lower doses.
1 ml of solution MultiHance® contains: (0.5M) gadobenate dimeglumine 529 mg = gadobenic acid 334 mg + meglumine 195 mg. Viscosity at 37°C: 5.3 mPa
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
|
|
Drug Information and Specification |
| NAME OF COMPOUND |
Gadobenate dimeglumine, Gd-BOPTA, E7155 |
| DEVELOPER |
Bracco |
| CENTRAL MOIETY |
Gd2+ |
| CONTRAST EFFECT |
T1, predominantly positive enhancement |
| RELAXIVITY |
r1=9.7, r2=12.5, B0=0.5 T |
| PHARMACOKINETIC |
Extracellular, hepatobiliary |
| OSMOLALITY |
1970 mosm/kg |
| CONCENTRATION |
334 mg/ml |
| DOSAGE |
0.05 mmol/kg for Liver MRI
0.1 mmol/kg for CNS MRI |
| PREPARATION |
Solution for injection |
| INDICATION |
CNS, Liver MRI |
| DEVELOPMENT STAGE |
For sale |
| DISTRIBUTOR |
See below |
| PRESENTATION |
Vials of 5, 10, 15 and 20 mL, and 50 & 100 mL Multipacks (Pharmacy Bulk Package)
|
| DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT! |
|
|
|
| | | |
| Further Reading: |
Basics:
|
|
News & More:
| | | | | | •• There is 1 news about 'MultiHance®'. | |
| | |
| Nonionic Intravenous Contrast Agents | |
| |
|
Radiographic low-osmolar nonionic contrast agents have less side effects and fewer nephrotoxicity than ionic, high-osmolar agents. Gadolinium-based MRI contrast agents have a different formulation from iodinated X-ray contrast media, and there is no known cross sensitivity between these two types of contrast agents. Intravenous MRI contrast agents, specifically the gadolinium chelates have a high safety and lack of nephrotoxicity compared with X-ray contrast media.
The used gadolinium chelates differ in following properties: linear (e.g., gadodiamide and gadoversetamide have nonionic linear structures) vs. macrocyclic cores, and ionic vs. nonionic types. The nonionic molecules have lower osmolality and viscosity, which increase digestibility at greater concentrations, and make faster bolus injections conceivable.
The macrocyclic molecules (e.g., gadoteridol has a nonionic macrocyclic ring structure) are more stable and show fewer tendencies to dissociate free Gd.
See also ProHance®, Omniscan®, OptiMARK®, Ionic Intravenous Contrast Agents.
See also the related poll result: 'MRI will have replaced 50% of x-ray exams by' |
| | | |
| Further Reading: |
Basics:
|
|
News & More:
| | | |
| |
|
| |
| Positive Oral Contrast Agents | |
| |
|
Types of oral contrast agents with positive signal enhancement:
| |
|
Ideal oral contrast agents are immiscible with water, biologically inert, have a low viscosity and surface tension. Oral positive contrast agents may improve the separation of bowel loops, the detection of polyps in colon MRI or the assessment of inflammatory bowel in the small intestine.
Several positive oral contrast agents are available and they are safe to use, for example gadolinium solution, ferric ammonium citrate, different oil emulsions and pediatric formula.
Unfavourably motion artifacts caused by respiration and peristalsis may be increased in MR imaging. In addition, the signal of the positive contrast medium may decrease caused by dilution in gastrointestinal (GI) secretions. With the use of contrast agents that are immiscible with water, no dilution and accompanying signal loss occur even when the contrast agent is in contact with the intraluminal contents of the GI tract.
Another disadvantage may be residual substances in the bowel, resembling masses when enclosed by bright signal. In addition, positive contrast agents may have a similar signal as bright masses, which make their (e.g. lipoma) detection difficult.
See also Gastrointestinal Paramagnetic Contrast Agents, Combination Oral Contrast Agents, Gastrointestinal Diamagnetic Contrast Agents. |
| | | | | |
| Further Reading: |
Basics:
|
| | |
| |
|
|
MRI Resources |
|
| | | | | | | 1 - 5 (of 5) Result Pages : [1] |
| |
|
| |
 | Look
Ups |
| |
bottom
(.pdf)
Random Page
top